Brain-targeted delivery of peptides

American Pharmaceutical Review

Volumn 9, Issue 1, 2006, Pages 100-104

  Bodor, Nicholas ^a   Buchwald, Peter ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b IVAX Research Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENKEPHALIN; KYOTORPHIN; NALOXONE; NEUROPEPTIDE; OCTREOTIDE; PROTIRELIN;

BLOOD BRAIN BARRIER; BRAIN; CHEMICAL DELIVERY SYSTEM; DRUG DELIVERY SYSTEM; GENE TARGETING; HUMAN; MOLECULAR DYNAMICS; OXIDATION REDUCTION REACTION; RETINA; REVIEW;

EID: 55549119287     PISSN: 10998012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Regier, D. A.; Boyd, J. H.; Burke, J. D., Jr.; Rae, D. S.; Myers, J. K.; Kramer, M.; Robins, L. N.; George, L. K.; Karno, M.; Locke, B. Z. One-month prevalence of mental disorders in the United States. Arch. Gen. Psychiat., 1988, 45, 977-986.
2. Bodor, N.; Buchwald, P. Brain-targeted delivery: experiences to date. Am. J. Drug Deliv., 2003, 1, 13-26.
3. Egleton, R. D.; Davis, T. P. Development of neuropeptide drugs that cross the blood-brain barrier. NeuroRx, 2005, 2, 44-53.
4. Bodor, N.; Brewster, M. E. Problems of delivery of drugs to the brain. Pharmacol. Ther., 1983, 19, 337-386.
5. Bodor, N.; Brewster, M. E. Chemical delivery systems. In Targeted Drug Delivery; Juliano, R. L., Ed.; Springer: Berlin, 1991; Handbook of Experimental Pharmacology, Vol. 100, pp. 231-284.
6. Bodor, N.; Buchwald, P. Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems. Adv. Drug Deliv. Rev., 1999, 36, 229-254.
7. Bodor, N.; Buchwald, P. Retrometabolism-based drug design and targeting. In Burger's Medicinal Chemistry and Drug Discovery. Vol. 2, Drug Discovery and Drug Development, 6th Edition; Abraham, D. J., Ed.; Wiley: New York, 2003; 2, pp. 533-608.
8. Bodor, N.; Buchwald, P. Targeting of neuropharmaceuticals by chemical delivery systems. In Blood-Brain Interfaces: From Ontogeny to Artificial Barriers.; Dermietzel, R., Spray, D. C., Needergard, M., Eds.; Wiley-VCH: Weinheim, 2006; pp. 463-500.
9. Banks, W. A.; Kastin, A. J. Exchange of peptides between the circulation and the nervous system: Role of the blood-brain barrier. Adv. Exp. Med. Biol., 1990, 274, 59-69.
10. Brownlees, J.; Williams, C. H. Peptidases, peptides, and the mammalian blood-brain barrier. J. Neurochem., 1993, 60, 793-803.
11. Ermisch, A.; Brust, P.; Kretzschmar, R.; Rühle, H.-J. Peptides and blood-brain barrier transport. Physiol. Rev., 1993, 73, 489-527.
12. Witt, K. A.; Gillespie, T. J.; Huber, J. D.; Egleton, R. D.; Davis, T. P. Peptide drug modifications to enhance bioavailability and bloodbrain barrier permeability. Peptides, 2001, 22, 2329-2343.
13. Bodor, N.; Prokai, L. Molecular packaging: peptide delivery to the central nervous system by sequential metabolism. In Peptide-Based Drug Design: Controlling Transport and Metabolism; Taylor, M., Amidon, G., Eds.; American Chemical Society: Washington, DC, 1995; pp. 317-337.
14. Bodor, N.; Prokai, L.; Wu, W.-M.; Farag, H. H.; Jonnalagadda, S.; Kawamura, M.; Simpkins, J. A strategy for delivering peptides into the central nervous system by sequential metabolism. Science, 1992, 257, 1698-1700.
15. Prokai-Tatrai, K.; Prokai, L.; Bodor, N. Brain-targeted delivery of a leucine-enkephalin analogue by retrometabolic design. J. Med. Chem., 1996, 39, 4775-4782.
16. Prokai, L.; Ouyang, X.-D.; Wu, W.-M.; Bodor, N. Chemical delivery system to transport a pyroglutamyl peptide to the central nervous system. J. Am. Chem. Soc., 1994, 116, 2643-2644.
17. Prokai, L.; Ouyang, X.; Prokai-Tatrai, K.; Simpkins, J. W.; Bodor, N. Synthesis and behavioral evaluation of a chemical brain-targeting system for a thyrotropin-releasing hormone analogue. Eur. J. Med. Chem., 1998, 33, 879-886.
18. Prokai, L.; Prokai-Tatrai, K.; Ouyang, X.; Kim, H.-S.; Wu, W.-M.; Zharikova, A.; Bodor, N. Metabolism-based brain-targeting system for a thyrotropin-releasing hormone analogue. J. Med. Chem., 1999, 42, 4563-4571.
19. Yoon, S.-H.; Wu, J.; Wu, W.-M.; Prokai, L.; Bodor, N. Brain-targeted chemical delivery of Leu2, Pip3.-TRH: synthesis and biological evaluation. Bioorg. Med. Chem., 2000, 9, 1059-1063.
20. Wu, J.; Yoon, S.-H.; Wu, W.-M.; Bodor, N. Synthesis and biological evaluation of a brain-targeted chemical delivery system of Nva2.-TRH. J. Pharm. Pharmacol., 2002, 54, 945-950.
21. Prokai-Tatrai, K.; Perjési, P.; Zharikova, A. D.; Li, X.; Prokai, L. Design, synthesis, and biological evaluation of novel, centrally-acting thyrotropin-releasing hormone analogues. Bioorg. Med. Chem. Lett., 2002, 12, 2171-2174.
22. Prokai, L.; Prokai-Tatrai, K.; Zharikova, A. D.; Nguyen, V.; Perjesi, P.; Stevens, S. M., Jr. Centrally acting and metabolically stable thyrotropin-releasing hormone analogues by replacement of histidine with substituted pyridinium. J. Med. Chem., 2004, 47, 6025-6033.
23. Bodor, N.; Buchwald, P. All in the mind. Chem. Br., 1998, 34 (1), 36-40.
24. Chen, P.; Bodor, N.; Wu, W.-M.; Prokai, L. Strategies to target kyotorphin analogues to the brain. J. Med. Chem., 1998, 41, 3773- 3781.
25. Stewart, P. A.; Tuor, U. I. Blood-eye barriers in the rat: Correlation of ultrastructure with function. J. Comp. Neurol., 1994, 340, 566-576.
26. Takagi, H.; Shiomi, H.; Ueda, H.; Amano, H. A novel analgesic dipeptide from bovine brain is a possible Met-enkephalin releaser. Nature, 1979, 282, 410-412.
27. Buchwald, P.; Bodor, N. Octanol-water partition of nonzwitterionic peptides: Predictive power of a molecular size-based model. Proteins, 1998, 30, 86-99.